YCLOAK

Kilauea, one of the most active volcanoes in the world, began erupting Wednesday after a three-month pause, displaying spectacular fountains of mesmerizing, glowing lava that’s a safe distance from people and structures in a national park on the Big Island.

The U.S. Geological Survey’s Hawaiian Volcano Observatory said in a statement that a glow was detected in webcam images from Kilauea’s summit early in the morning, indicating that an eruption was occurring within the Halemaumau crater in the summit caldera.

The images show fissures at the base of the crater generating lava flows on the crater floor’s surface, the observatory said.

Before issuing the eruption notice, the observatory said increased earthquake activity and changes in the patterns of ground deformation at the summit started Tuesday night, indicating the movement of magma in the subsurface.

“We’re not seeing any signs of activity out on the rift zones right now,” said Mike Zoeller, a geologist with the observatory. “There’s no reason to expect this to transition into a rift eruption that would threaten any communities here on the island with lava flows or anything like that.”

All activity was within a closed area of Hawaii Volcanoes National Park.

“The lava this morning is all confined within … the summit caldera. So plenty of room for it still to produce more without threatening any homes or infrastructure,” said park spokesperson Jessica Ferracane. “So that’s the way we like our eruptions here.”

She said park officials are bracing for crowds to arrive because visitors can see the eruption from many overlooks.

“Kilauea overlook was spectacular this morning,” she said of the vast lava lake. “It was molten red lava. There’s several areas of pretty robust fountaining. It’s just really, really pretty.”

The lava lake, covering the crater floor over lava that remained from previous eruptions, measured about 150 hectares about 6 a.m., Zoeller said. It measured about 1,300 meters wide.

Word was getting out and parking lots were starting to fill up at the park, Ferracane said, adding that she expected long lines getting into the park by evening.

Since the park is open 24 hours a day, visitors can beat the crowds by visiting between 9 p.m. and sunrise, Ferracane said.

She reminded visitors to stay out of closed areas and remain on marked trails for safety reasons, including avoiding gases from the eruption.

Two small earthquakes jolted Janice Wei awake. As a volunteer photographer for the park who lives in the nearby town of Volcano, she was able to see fountains she estimated to be 46 meters high around 4:30 a.m.

The volcano’s alert level was raised to warning status and the aviation color code went to red as scientists evaluate the eruption and associated hazards.

Kilauea, Hawaii’s second largest volcano, erupted from September 2021 until last December. For about two weeks in December, Hawaii’s biggest volcano, Mauna Loa, also was erupting on Hawaii’s Big Island.

After a short pause, Kilauea began erupting again in January. That eruption lasted for 61 days, ending in March.

This eruption looks very similar, Zoeller said.

A 2018 Kilauea eruption destroyed more than 700 homes.

Before the major 2018 eruption, Kilauea had been erupting since 1983, and streams of lava occasionally covered farms and homes. During that time, the lava sometimes reached the ocean, causing dramatic interactions with the water. 
…

As communities in countries rich and poor face soaring costs from extreme weather and rising seas, governments are grappling with how to set up a new fund to tackle “loss and damage” driven by global warming.

The topic was for years controversial at U.N. climate talks, as wealthy nations rejected demands for “compensation” for the impacts of their high share of the planet-heating emissions that are turbo-charging floods, droughts and storms around the world.

However, at the COP27 climate summit in Egypt last November, a group of 134 African, Asian and Latin American states and small island nations finally won agreement on a new fund that will pay to repair devastated property, or preserve cultural heritage before it disappears forever.

But the details of where the money will come from and how it will be disbursed were left to be worked out by this December’s COP28 conference in Dubai.

As mid-year U.N. climate talks got underway in Bonn in June, Saleemul Huq, director of the Dhaka-based International Centre for Climate Change and Development, called on the United Arab Emirates to declare its intention for COP28 — which it will host — to create the “Dubai Loss and Damage Fund.”

Here’s why the issue of “loss and damage” has grown in importance this past decade — and where the sticking points in finding finance to address it could lie.

What is climate change “loss and damage”?

“Loss and damage” refers to the physical and mental harm that happens to people and places when they are not prepared for climate-driven impacts, and are unable to adjust the way they live to protect themselves from longer-term shifts.

It can occur both from fast-moving weather disasters made stronger or more frequent by warming temperatures — such as floods or hurricanes — as well as from slower-developing stresses like persistent drought and sea levels creeping higher.

A large share of “loss and damage” can be measured in financial terms, like the cost of wrecked homes and infrastructure.

But there are other non-economic losses that are harder to quantify, such as graveyards and family photos being washed away, or Indigenous cultures that could disappear if a whole community must move because their land is no longer habitable.

A June 2022 report released by a forum of 55 climate-vulnerable countries — from Bangladesh to South Sudan — found they would have been 20% wealthier had it not been for climate change and the $525 billion in losses inflicted on them by shifts in temperature and rainfall over the past two decades.

Often the poorest people lack the means to recover what they have lost, particularly as aid fails to keep up with growing needs, as seen with last year’s huge floods in Pakistan or the drought that has left tens of millions hungry in the Horn of Africa.

What funding is on offer when loss and damage happens — and how can more be raised?

So far there has been very little money available apart from aid provided through the international humanitarian system to respond to disasters — which every year faces shortfalls.

A 2022 study by anti-poverty charity Oxfam found that aid needs in response to weather disasters had skyrocketed more than eightfold in the last 20 years.

But U.N.-coordinated humanitarian emergency appeals are, on average, only 60% funded.

“There is not enough money for humanitarian action — even to do the first-phase response [to disasters], never mind the preparedness, resilience [and] longer-term early recovery piece,” said Debbie Hillier, who manages flood resilience programs for Mercy Corps.

According to a 2018 study by researchers at the Basque Centre for Climate Change, the costs of loss and damage in low- and middle-income countries could reach between $290 billion and $580 billion a year by 2030.

But rich countries are already struggling to meet a goal to channel $100 billion annually to vulnerable countries for reducing emissions and adapting to climate change.

Some donor countries, including a few European nations, Canada and New Zealand, have already agreed to provide loss and damage funding to poorer nations – although so far, those pledges total only about $275 million.

Given this, climate justice activists have long argued for the need to find innovative sources for loss and damage funding, based on levies and taxation.

Those include a controversial proposal — backed by the U.N. chief — for rich governments to tax the windfall profits of fossil fuel companies.

Other ideas that have gained ground include levying a small fee on international flights – which contribute to climate-heating emissions – and a global tax on financial market transactions, which could be distributed by the new fund.

The most concrete loss and damage funding scheme so far, the “Global Shield Against Climate Risks”, aims to boost insurance coverage for vulnerable countries and communities, attracting about $200 million at its COP27 launch, largely from Germany.

It will expand initiatives — from subsidized insurance coverage to stronger social protection schemes and pre-approved disaster financing — that can swiftly channel support to disaster-hit poorer countries’ own contingency plans.

But many climate campaigners say insurance cannot be a lasting answer, with losses expected to soar and even become uninsurable as climate disasters intensify.

What are the obstacles to setting up a loss and damage fund?

A “Transitional Committee” is meeting regularly this year to work out the form and scope of the new loss and damage fund, and how to fill its coffers.

Observers say the discussions have progressed constructively — and are hoping this month’s Bonn climate talks will add political momentum. But there is disagreement on which parts of loss and damage finance should fall under the new fund’s remit.

Some countries, notably the United States, want the fund to focus tightly on two key areas less well-covered by humanitarian agencies — “slow onset” disasters, from desertification to islands sinking as seas rise, and “non-economic losses”.

That would also include support for communities — or even whole island nations — to relocate should they no longer be able to continue living in their current homes.

Climate justice campaigners and others, meanwhile, are pushing for the new fund to have a broader scope, which would include helping finance the humanitarian response to climate disasters as well as efforts to cover gaps, especially in terms of building resilience.

A report last month by the Zurich Flood Resilience Alliance outlined lessons learned by the aid sector that could help the new loss and damage fund operate effectively.

Its recommendations included a warning to donors not to re-label their humanitarian aid as loss and damage funding, and to find new sources of finance.

It also stressed the need to use existing systems to deliver aid on the ground fast, find ways to get funding to fragile and conflict-hit states, and work with local groups.

The key will be to agree on how loss and damage action can both benefit from — and amplify — the work already being done by humanitarian agencies to protect vulnerable communities, experts say.

“We can’t allow the accountability to be shifted outside the [U.N. climate] system — for a very simple reason: 90% of disasters we are facing today are climate-related,” said Harjeet Singh, head of global political strategy for Climate Action Network International.

“The loss and damage fund has to be the top-level mechanism that should have oversight on whether people are getting sufficient support or not.”
…

Moving around metropolitan areas can present challenges for individuals who are obese or have height limitations, as many public spaces are not designed to accommodate their needs. However, a new law adds weight and height to the list of characteristics that are protected from discrimination in New York City. Aron Ranen has the story.
…

China, where COVID-19 was first identified in humans more than three years ago, expects its current wave of infection to hit as many as 65 million cases per week by late June, according to official accounts of models presented at a medical conference.

While that may be an exhausting number to a post-pandemic world wearied by a still rising toll of 767 million confirmed cases and more than 6.9 million deaths, the predicted onslaught in China comes with less severe symptoms, Wang Guiqiang, director of the Department of Infectious Diseases at Peking University First Hospital, told the official newspaper Beijing Daily.

And, experts say, the outbreak is likely to be confined to China. Raj Rajnarayanan, assistant dean of research and associate professor at the New York Institute of Technology and a top COVID-variant tracker, told Fortune that when it comes to XBB variants, “the rest of the world has seen them all.” But up until recently, “China hasn’t.”

Respiratory disease specialist Zhong Nanshan, who spoke on May 22 at a conference in the southern city of Guangzhou, said the current wave of infections that started in late April was “anticipated.” His modeling suggested that by the end of June, the weekly number of infections will peak at 65 million, according to the official Global Times.

After Beijing relaxed the draconian lockdowns enforced under its “zero-COVID” policy, an omicron variant different from the current one ripped through China in December 2022 and January 2023.

About 80% of China’s 1.4 billion people were infected during that wave, Wu Zunyou, chief epidemiologist at the Chinese Center for Disease Control and Prevention, said in January, CNN reported. Patients packed hospitals and families waited for days to cremate those who died.

The latest COVID wave is something most people do not take seriously, said Mr. Lin, who requested anonymity due to the sensitivity of the issue. The resident of Quanzhou in Fujian province said, “They go about their activities normally and don’t do any protection. No one wears masks.”

Mr. Lin told VOA Mandarin he was infected in mid-December 2022, soon after Beijing lifted the lockdowns that had sent the world’s second-largest economy into a tailspin.

He realized he was infected — again — in May. Mr. Lin said he knew others who were likely reinfected and didn’t even bother to take a COVID test because their symptoms were so mild.

Mr. Zhang, who was infected for the first time in December, told VOA Mandarin he was infected a second time on a business trip to Shanghai and Beijing in May. The Hunan province resident, who asked to use a pseudonym to avoid attracting official attention, thought he had caught a cold because of the air conditioning he encountered on his trip.

But he took a test while still in Beijing and with a positive result, ended up at a hospital where he said a doctor told him, “People all over the country are like this. No need for medical attention at all. Just go home.”

After suffering four days with insomnia, loss of appetite and recurring fever, Mr. Zhang went to another Beijing hospital. Admitted, he was given Paxlovid, an anti-coronavirus drug developed by Pfizer.

“I took the medicine at noon and felt relieved at night,” he told VOA Mandarin.

During his hospital stay, Mr. Zhang said, “All the infectious disease wards were full, and there was a long queue to get an appointment. The hospital used wards of other departments for patients from the Infectious Diseases Department.”

Jin Dong-yan, a biochemistry professor with the Li Ka-shing Faculty of Medicine at the University of Hong Kong, told VOA Mandarin there is not much difference between the current situation in China and in the U.S., but the Chinese media devote more coverage to the outbreak.

Jin said, “In fact, looking at the data, the U.S. has experienced about four peaks after the outbreak last year, but each peak is getting smaller and smaller.”

The United States, by comparison, was reporting more than 5 million cases a week at its most recent peak in January.

The World Health Organization declared COVID-19 over as a global health emergency on May 5.

Like the U.S., China stopped providing weekly case updates in May, making it difficult to know the true extent of the current outbreak.

The U.S. Centers for Disease Control and Prevention recorded more than 1.1 million deaths in the U.S. involving COVID-19 from January 4, 2020, to May 27, 2023. 

In China, from January 3, 2020, to May 31, 2023, there have been almost 100 million confirmed cases of COVID-19, with more than 120,000 deaths reported by Beijing to WHO.

Adrianna Zhang contributed to this report.
…

New advances in the fight against a range of cancers have been revealed at the annual meeting of the American Society of Clinical Oncology (ASCO), which wraps up in Chicago on Tuesday.

Here are some of the announcements that have most excited experts.

Lung cancer

One of the trial results that caused a stir in Chicago has raised hopes for a new weapon against lung cancer, the deadliest of all cancers.

The treatment osimertinib was shown to halve the risk of death from a certain type of lung cancer when taken daily after surgery to remove the tumor.

Developed by the pharmaceutical group AstraZeneca, the daily pill targets patients with non-small cell cancer — by far the most common type — as well as a mutation of their epidermal growth factor receptor, or EGFR.

Iris Pauporte, head of research at France’s League Against Cancer, told AFP the advance was a “big ray of hope” for this type of cancer, for which progress has been slow.

Muriel Dahan, head of research at Unicancer, said that if the results are confirmed, it “should change” common practice in treating this kind of lung cancer.

Systematic testing for the EGFR mutation would also become necessary for lung cancer patients, she added.

Brain cancer

Another treatment, called vorasidenib, was found to significantly prolong the progression-free survival of patients with brain tumor glioma, according to clinical trial results.

The daily pill, developed by French pharma firm Servier, aims to block an enzyme responsible for the progression of some brain cancers, which have been particularly difficult to treat.

Patrick Therasse, Servier’s vice-president of oncology research, told AFP that there “have been few therapeutic advances for brain tumors over the last 20 years.”

“Thanks to our targeted treatment, patients avoided cancer progression for 27.7 months, compared to 11.1 months” for those taking a placebo, he added.

Fabrice Andre, head of research at France’s Gustave Roussy cancer center, said “precision medicine opens a door for a disease for which there was nothing until now.”

“It means that science can unblock situations that were catastrophic,” he told AFP.

Unicancer’s Dahan said it was important to “remain cautious” but added that “this could become the new therapeutic standard — depending on further trials.”

Breast cancer

Preliminary trial results also released in Chicago indicated the drug ribociclib reduced the risk of breast cancer recurring by 25 percent for a large group of early-stage survivors.

The drug, developed by Swiss pharmaceutical maker Novartis, is already widely approved around the world. It was tested in combination with hormonal therapy.

ASCO expert Rita Nanda said it was a “very important and practice-changing clinical trial.”

Cervical cancer

There was also good news for patients with early-stage cervical cancer with a low risk of progression.

There was no greater risk of the cancer returning for patients who get a simple hysterectomy, in which the uterus and cervix are removed, than a radical hysterectomy, in which the uppermost part of the vagina is also removed, according to phase three trials.

League Against Cancer’s Pauporte said this was “good news,” adding that “it shows that it’s not just progress involving drugs that was important.”

Ovarian cancer

A trial also presented at ASCO showed that taking the antibody treatment mirvetuximab soravtansine significantly improved the survival rate of patients with ovarian cancer, a particularly deadly form of cancer.

ASCO expert Merry Jennifer Markham said the treatment “demonstrates progress and offers hope for these patients.”

Rectal cancer

Study results released in Chicago indicated that patients with locally advanced rectal cancer could receive chemotherapy without getting radiation therapy before undergoing surgery.

This would spare patients from the brutal side effects of radiation.

Vaccines

Vaccines that treat existing cancer have long been a goal of the medical community.

Preliminary studies announced at the ASCO meeting involved vaccines targeting lung cancer, head and neck cancers, brain tumor glioblastoma and the cancer-causing HPV virus.

Christophe Le Tourneau, an oncologist at France’s Curie Institute which presented a study about a vaccine for a certain form of HPV, said there has been “significant technological progress” in the area recently.

“Therapeutic vaccines, we talk about them more and more, and there are more and more trials in progress,” he said.
…

Global leaders in the battle against global warming convened in Bonn, Germany, on Monday for the start of the final phase of a two-year long assessment of the progress being made to limit rising temperatures.

The annual Bonn Climate Change Conference is part of the “global stocktake” — a process by which countries around the world assess how much progress has been made toward compliance with the 2015 Paris Agreement, a worldwide effort to prevent global temperatures from exceeding 1.5 degrees Celsius above the pre-industrial era average.

“The global stocktake is an ambition exercise. It’s an accountability exercise. It’s an acceleration exercise,” U.N. Climate Change Executive Secretary Simon Stiell said in a statement. “It’s an exercise that is intended to make sure every Party is holding up their end of the bargain, knows where they need to go next and how rapidly they need to move to fulfill the goals of the Paris Agreement.”

However, Stiell warned that the findings will only be meaningful if they are paired with action.

“The global stocktake will end up being just another report unless governments and those that they represent can look at it and ultimately understand what it means for them and what they can and must do next. It’s the same for businesses, communities and other key stakeholders,” he said.

The stocktake will conclude in November, when the annual U.N. Climate Change Conference (COP28) is held in Dubai, United Arab Emirates.

Stocktake process

The global stocktake is a two-year process that happens once every five years, as dictated by the Paris Agreement. It has three parts: an information collection and preparation phase, a technical assessment and a consideration of the process’s outputs.

The stocktake began in 2021, with countries, NGOs, experts and other stakeholders gathering information about efforts currently underway to slow global warming. This includes efforts by individual countries to meet the emission-reduction goals they have agreed to at previous COP gatherings — known as nationally determined contributions (NDCs) — as well as challenges and barriers to meeting those goals, and data about new mitigation techniques.

At last year’s Bonn Climate Conference, technical experts began to assess the findings, a process meant to be finalized over this year’s 10-day gathering.

The consideration of the findings will begin immediately following the conference and will be translated into recommendations for further action meant to be finalized in Dubai later this year.

No mystery

While the final details of the global stocktake will not be published until later this year, there is little mystery about what the process is likely to uncover. An interim report published in March found that progress has been “significant yet inadequate” in terms of reaching the goals set out in the Paris Agreement.

“While the remarkable speed with which the Paris Agreement entered into force in 2016 demonstrates a broad commitment, and Parties are making progress in implementation, we as a global community are not on track to meet its long-term goals,” the report found.

Still, experts said that there are reasons for optimism.

“The big value out of the global stocktake is that it’s also meant to be telling us not only where we are and where we need to be, but how to get there. What we’re hearing through the process so far is that there are solutions across all sectors and all [greenhouse] gases,” Maggie Ferrato, a manager for global climate cooperation at the Environmental Defense Fund, told VOA.

“And really the challenge is to kind of distill really clear signals from the wealth of information that’s out there on the highest impact opportunities that should be incorporated into Nationally Determined Contributions in the next round.”

More upbeat assessment

The Bonn Conference comes just a few weeks after a pair of reports from U.N.-affiliated research organizations painted grim pictures of the planet’s climate future.

In March, the Intergovernmental Panel on Climate Change warned that the planet is getting close to being unable to avoid a temperature increase of more than 1.5 degrees Celsius and predicted that more negative consequences of global climate change will soon become apparent. It said that the changes will frequently harm poor and vulnerable populations across the globe, many of which have contributed little to global warming.

Last month, the World Meteorological Organization issued a report that found a two-thirds chance the world will experience at least one year of temperatures averaging more than 1.5 degrees over the pre-industrial average within the next five years.

Michael Mehling, deputy director of the Center for Energy and Environmental Policy Research at the Massachusetts Institute of Technology, told VOA that organizers of the Bonn Conference and of the COP process in general seem to realize unremitting gloom about the climate future may be doing more harm than good.

“I think there’s certainly a realization that just always saying, ‘We’re far behind. Everything looks terrible,’ is losing some impact,” he said.

Mehling said that he anticipates a report that recognizes that progress has been made and that achieving a less ambitious goal of keeping warming below 2 degrees — a level that scientists warn could be catastrophic — is achievable.

“I would probably anticipate some sort of a split message that suggests that we have to continue holding the line and staying [focused] on 2 degrees, but we can achieve that,” he said. “But it doesn’t look good for 1.5, unless we dramatically change what we’re doing. That’s what I expect to be the headline message.”
…

A pill has been shown to halve the risk of death from a certain type of lung cancer when taken daily after surgery to remove the tumor, according to clinical trial results presented on Sunday.

The results were unveiled in Chicago at the largest annual conference of cancer specialists, hosted by the American Society for Clinical Oncology.

Lung cancer is the form of the disease that causes the most deaths, with approximately 1.8 million fatalities every year worldwide.

The treatment developed by the pharmaceutical group AstraZeneca is called osimertinib and is marketed under the name Tagrisso. It targets a particular type of lung cancer in patients suffering from so-called non-small cell cancer, the most common type, and showing a particular type of mutation.

These mutations, on what is called the epidermal growth factor receptor, or EGFR, affect 10% to 25% of lung cancer patients in the United States and Europe, and 30 to 40% in Asia.

The clinical trial included some 680 participants at an early stage of the disease (stages 1b to 3a), in more than 20 countries. They had to have been operated on first to remove the tumor, then half of the patients took the treatment daily, and the other a placebo.

The result showed that taking the tablet resulted in a 51% reduction in the risk of death for treated patients, compared to placebo.

After five years, 88% of patients who took the treatment were still alive, compared to 78% of patients who took the placebo.

These data are “impressive,” said Roy Herbst of Yale University, who presented them in Chicago. The drug helps “prevent the cancer from spreading to the brain, to the liver, to the bones,” he added at a press conference.

About a third of cases of non-small cell cancers can be operated on when detected, he said.

“It is hard for me to convey, I think, how important this finding is,” said Nathan Pennell of the Cleveland Clinic Foundation at the press conference.

“We started entering the personalized therapy era for early-stage patients,” said Pennell, who did not take part in the trials, and noted that “we should firmly close the door on one-size-fits-all treatment for people with non-small cell lung cancer.”

Osimertinib is already authorized in dozens of countries for various indications, and has already been given to some 700,000 people, according to a press release from AstraZeneca.

Its approval in the United States for early stages in 2020 was based on previous data that showed an improvement in patient disease-free survival, that is, the time a patient lives without a recurrence of cancer.

But not all doctors have adopted the treatment, and many were waiting for the data on overall survival that was presented on Sunday, said Herbst.

He stressed the need to screen patients to find out if they have the EGFR mutation. Otherwise, he said, “we cannot use this new treatment.”

Osimertinib, which targets the receptor, causes side effects that include severe fatigue, skin rashes or diarrhea.
…

Tour de France organizers have set up an anti-COVID protocol for this year’s race, with riders and team staff banned from signing autographs and eating out of their hotels, a source with direct knowledge of the matter told Reuters Saturday. 

Riders and staff members were allowed out of their hotels last year. Access to the paddock at the start of the stages was open to reporters until midway through the race, when organizers decided to close it to “fight against the propagation of COVID-19.” 

Access to the paddock will be allowed when the Tour starts in Bilbao, Spain, on June 29, with everyone required to wear a mask. 

“For all the team members: Respect a confinement – Limit the interactions outside the race bubble. No eating out. Respect social distancing at the hotel,” the chart, seen by Reuters, said. 

“Do not get too close to the spectators – Social distancing, no selfies, no autograph.” 

On Friday, France reported 3,204 COVID-19 cases in the country. At this time last year, there were about 25,000 reported daily cases in France. 

Giro d’Italia organizers last month set up an anti-COVID protocol near the halfway point of the race after overall leader Remco Evenepoel pulled out after testing positive for coronavirus. 
…